"Too often, discussions about costs do not illustrate the trade-offs."
High Prices Continue to Limit Access to Hepatitis C Treatment
The Washington Post takes a deeper dive on the issues highlighted in the Drug Pricing Lab's budget allocator tool.
Sarah Jane Tribble published an in-depth article on the challenges faced by Louisiana's health secretary, Dr. Rebekah Gee, in finding money to treat the state's patients with Hepatitis C. The DPL's Louisiana Budget Allocator, an interactive tool to assess the human costs of these budget tradeoffs, "shows how millions of dollars would need to be shifted in the state's discretionary budget to pay for those treatments. For instance, cutting K-12 funding by $26 million would cover treatments for 3,176 hepatitis C patients. Too often, [Dr. Peter Bach] said, discussions about costs do not illustrate the trade-offs. 'These numbers are so large that it's very difficult to think about them proportionately.'"
Read the full article here.